One approach to overcome tumor escape is the use of immune checkpoint inhibitors (ICIs) to block the inhibitory factors that hamper the host's immune response, such as CTLA‐4, programmed cell death protein 1 (PD‐1), and its ligand, PD‐L1. The gene discussed is PDCD1; the disease is neoplasm.